A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivation, Inc.
• Collaborator: Pfizer

Criteria

Inclusion Criteria:

• Moderate-to-Severe Alzheimer's disease

• Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive

• Stable on donepezil for at least 6 months

Exclusion Criteria:

• Other causes of dementia

• Major structural brain disease

• Unstable medical condition or significant hepatic or renal disease